ArticleOphthalmology science2026
A Continuous Severity Index for Keratoconus Diagnosis Based on Kolmogorov-Arnold Networks in a Chinese Population.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a continuous, interpretable severity index for keratoconus (KC) using a Kolmogorov-Arnold Network (KAN) to improve early detection and disease staging, particularly for forme fruste keratoconus (FFKC) in refractive surgery screening. Design: A retrospective case-control study. Participants: A total of 384 eyes from 384 participants were included: 101 keratoconic eyes, 132 FFKC eyes (fellow eyes of KC patients), and 151 normal control eyes derived from refractive surgery candidates with at least 2 years of uneventful follow-up. Methods: Corneal tomographic parameters were obtained using Pentacam HR, and biomechanical parameters using Corvis ST. A KAN model was trained using categorical diagnostic labels (normal, FFKC, and KC) to generate a continuous, dimensionless Continuous Severity Index (CSI). Continuous Severity Index performance was compared with established indices, including Corvis Biomechanical Index, Corvis Biomechanical Index for Chinese populations, Tomography and Biomechanical Index, Tomography and Biomechanical Index for Chinese populations, and Stress-Strain Index, using receiver operating characteristic analysis. Feature attribution analysis was performed to explore stage-dependent parameter contributions. Main Outcome Measures: Area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and optimal cutoff values for differentiating disease stages. Results: Continuous Severity Index achieved an AUC of 1.000 for distinguishing KC from normal eyes, and 0.859 for distinguishing FFKC from normal eyes, outperforming all conventional biomechanical and tomographic indices. In combined screening tasks, CSI demonstrated superior performance in identifying any ectatic change (FFKC + KC vs. normal, AUC = 0.920) and advanced disease (KC vs. normal + FFKC, AUC = 0.998). Feature attribution analysis further revealed a stage-dependent shift in dominant contributors, with biomechanical parameters prevailing at lower CSI levels and tomographic asymmetry features increasingly governing advanced disease. Conclusions: The KAN-derived Continuous Severity Index enables unified, continuous, and interpretable quantification of KC severity, outperforming existing indices in both early screening and disease staging. By capturing the biologically coherent progression from biomechanical instability to morphological deformation, CSI provides a clinically meaningful tool for refractive surgery screening and KC management. Financial Disclosures: The authors have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.